Skip to content
Open in App
Royalty Pharma logo

Royalty Pharma

web2

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovatio...

Symbol · RPRX
Company profile

About

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Daraxonrasib Phase 3 RASolute 302 positive results

KEY STEP

On April 13, 2026, Revolution Medicines reported positive Phase 3 RASolute 302 results for daraxonrasib in previously treated metastatic pancreatic cancer. The result triggered a $250 million Royalty Pharma funding tranche and increased its tiered royalty rights.

Roadmap reference

Daraxonrasib receives FDA approval for metastatic pancreatic adenocarcinoma

KEY STEP

On August 26, 2026, the FDA approved Rasonque, or daraxonrasib, for adults with metastatic pancreatic adenocarcinoma who had received at least one prior systemic therapy or were not candidates for multiagent systemic therapy. The approval followed the positive Phase 3 RASolute 302 results and represents a regulatory milestone for a therapy tied to Royalty Pharma’s funding agreement with Revolution Medicines.

Roadmap reference
People

Company team

CM

Catherine M. Engelbert

Independent Director

Company leadership profile.

TW

Ted W. Love

Lead Independent Director

Company leadership profile.

BL

Bonnie L. Bassler

Independent Director

Company leadership profile.

PL

Pablo Legorreta

Founder, Chairman of the Board & CEO

Company leadership profile.

GN

Gregory Norden

Independent Director

Company leadership profile.

DC

David Charles Hodgson

Independent Director

Company leadership profile.

VC

Vladimir Coric

Independent Director

Company leadership profile.

EH

Elizabeth H. Weatherman

Independent Director

Company leadership profile.

CH

Carole Ho

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Royalty Pharma.

Orbitrum research

Experts evaluating Royalty Pharma

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment